Global Awareness. Local Impact.

CLA's mission is to promote disease awareness, prevention, education, advocacy, and research. Headquartered in Pittsburgh, the Community Liver Alliance has grown to have a national presence while still holding true to a mission to invest in local communities and give voice to patients and providers.

Upcoming Event:

Updatred
Click here for more information!

Events Search and Views Navigation

Event Views Navigation

Today

Fresh-a-Fare

Jamison Lamb Farm 171 Jamison Lane, Latrobe, PA, United States

Saturday, June 24, 2023 6:00-8:00 p.m. Jamison Lamb Farm 171 Jamison Ln Latrobe, PA 15650 $100 per ticket Tickets are limited to a max of 50 guests Register now! Fresh-a-Fare […]

Treating HCV in a Primary Care Setting

Virtual , United States

Hosted by Matthew Barnes, CRNP Crossroads Treatment Center   Virtual via Zoom - Register now!   *** Industry partners must have an exhibit or sponsorship to participate in the Community […]

HCV Provider Networking Meeting

Virtual , United States

Opportunities to discuss what is new in the Hep C space with other professionals.  Each meeting we will focus on one particular organization and their work, with a collaborative discussion […]

HCV Roundtable with the Expert

Virtual , United States

Presented by Michael Babich, MD Allegheny Health Network   Registration coming soon!   *** Industry partners must have an exhibit or sponsorship to participate in the Community Liver Alliance programs and events. […]

Viral Hepatitis Summit (Pittsburgh, PA)

Cambria Hotel 1320 Centre Ave, Pittsburgh, PA, United States

The Community Liver Alliance in collaboration with the National Viral Hepatitis Roundtable, MidSouth Liver Alliance, Hep B Foundation,  National Harm Reduction Coalition, Community Education Group,  and other key stakeholders representing […]

Advocacy

Learn More

News & Information

News & Information

Ask Congress to Support the LIVER Act

Ask Congress to Support the Liver Illness Visibility, Education, and Research (LIVER) Act What is the Liver Illness Visibility, Education, and Research (LIVER) Act?The LIVER Act is a public health

Read More »
November 17, 2021

Advocacy

Liver Disease Does Not Discriminate
There is 80 to 100 million people in the USA that have Fatty Liver Disease and most do not even know they have it. Liver Disease does not discriminate. It affects any age, social economics and race. Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time.
COVID-19 Response
Ensure funding for COVID-19 and liver disease public health programs, research, vaccine dissemination; ensure that people living with liver disease are not disproportionately impacted and do not experience unnecessary or discriminatory health care or treatment disruptions.
Health Disparities
Address inequities in the care of people impacted by liver disease, especially the excess incidence rate of liver cancer in black men in America.
Liver Health Policy
Advance the U.S. NASH Action Plan, and ensure patients with liver disease perspectives are represented in relevant legislative packages: COVID-19, diabetes, and obesity.
Liver Health Regulations
Work with regulators to establish logical pathways to consistently approve therapies for liver diseases, particularly rare liver diseases.
Research Funding
Advocate for funding that ensures meaningful growth of vital liver disease research and the improving of liver health.
Transplant
Urgently respond to the inequities that impact organ transplantation; modernize the U.S. Organ Donation system, improve care for transplant patients, and increase the number of available organs.
Viral Hepatitis
Increase support for hepatitis programs and raise awareness of viral hepatitis; advocate for the elimination of viral hepatitis .
Value
Advance health care policies that reflect each person’s unique needs and drive access to personalized, patient-centric care.
Patient Access and Reimbursement
Support policy solutions that curb patients’ health care expenses; advocate for the smoothing and capping of out-of-pocket costs in Medicare Part D.
Previous
Next
Learn More
0
PEOPLE IN USA WITH LIVER DISEASE
0
PEOPLE IN USA WITH FATTY LIVER DISEASE
0 %
RISE IN LIVER CANCER SINCE 1980
thumbnail_candy
a5b522_bb2badba75194f0ca50fa9f4b1eb9bd3_mv2_d_5184_3456_s_4_2 (1)
a5b522_3be131b09ce34a6381cb85f997038b37_mv2_d_4000_3000_s_4_2
CLA Event 4
CLA Event 2
CLA Event 3
CLA Event 1
20220727_125343
Previous image
Next image